The Commercialization Gaps MedTech Founders Keep Missing with Ryan Roghaar

Why can a MedTech company have promising technology, a strong team and investor interest, yet still lose momentum when it matters most?

Ryan Roghaar joins Christian Espinosa to examine the commercialization gaps that can quietly weaken a medical device company long before the technology itself becomes the problem.

Ryan explains why companies often move through fundraising, regulatory strategy, sales and market entry in the wrong sequence, and why inconsistencies between a pitch deck, website, evidence and buyer messaging can immediately create doubt.

The conversation explores what happens when claims outpace evidence, why MedTech companies struggle to define exactly who they are selling to, and how cybersecurity and AI are adding entirely new layers of risk to commercialization.

In This Episode:

07:43 Why Ryan moved into MedTech

10:32 Moving from marketing agency to MedTech consultancy

11:32 Why devices fail outside the technology itself

12:41 Does MedTech commercialization follow a sequence?

16:08 The evidence gap inside MedTech companies

17:10 How investors pressure-test startups

19:55 When a company tells four different stories

23:36 Can cybersecurity become a commercial differentiator?

24:11 Why medical device hacking feels different

27:24 Cybersecurity risks from MRIs to brain implants

32:21 The three biggest commercialization gaps Ryan is seeing

35:57 Why unclear buyers dilute your message

39:08 The pressure to take the wrong customer

42:47 Ryan’s three key takeaways for MedTech companies